- Company
- Takeda rejoins KRPIA after 5 years
- by Eo, Yun-Ho Nov 24, 2020 09:02am
- Takeda Pharmaceuticals Korea is returning to Korean Research-based Pharmaceutical Industry Association (KRPIA). The pharmaceutical industry sources recently reported Takeda has officially joined KRPIA as a member company. The company is gaining back its member company status as well. The KRPIA membership was inherited from Shire Phar
- Company
- An employee at drug company earns average KRW 41M
- by Chon, Seung-Hyun Nov 24, 2020 09:02am
- Apparently, the government statics say the average annual salary of the South Korean pharmaceutical industry is 41.4 million won. It was just shy of the general industry average. Depending on the pharmaceutical companies, some had average salary gap over 10 million among their employees. A university undergraduate’s average salary started from
- Company
- Daewoong succeeded in evading patent for Belkyra
- by Kim, Jin-Gu Nov 24, 2020 09:01am
- Daewoong once again succeeded in patent evasion of 'Belkyra (Deoxycholic acid)', an injection for improving submandibular fat. The original company, Allergan, tried to defend itself through 'divisional application' but failed. According to the pharmaceutical industry on the 23rd, the Intellectual Property Trial and Appeal Board recen
- Opinion
- [Reporter's View]Drugs fluctuating prices should be excluded
- by Lee, Hye-Kyung Nov 24, 2020 09:01am
- The lawsuit for canceling eye drops’ price ended with the Supreme Court's ruling. Recently, the Supreme Court did not accept the appeal of 20 pharmaceutical companies, including Kookje, filed against the government to cancel a lawsuit for canceling the disposition of lowering the upper limit on the reimbursement of eye drops. After the defea
- Policy
- The Health and Welfare Committee, postponed to 26th
- by Lee, Jeong-Hwan Nov 24, 2020 09:01am
- The Health and Welfare Committee of the National Assembly suffered a lapse of resolution of the budget for 2021 by the relevant government ministries on the afternoon of the 19th, and the subcommittee for legal review, which had been operating from this morning, also decided to suspend it without reopening. Ki-yoon Kang, a member of Peopl
- Policy
- "Let's develop new drugs with sales of ₩1 trillion"
- by Lee, Jeong-Hwan Nov 24, 2020 09:00am
- President Moon Jae-in announced that by 2025, the government will cultivate 47,000 human resources in the bio industry and increase the bio R&D budget to &8361;1.7 trillion, an additional &8361;400 billion from this year. In particular, he expressed his ambition to actively help the development of new blockbuster drugs with annual sales
- Company
- Will Sanofi's CHC division become an opportunity for growth?
- by Nov 24, 2020 09:00am
- Sanofi began to gain attention afterward as Sanofi started to incorporate the independent consumer healthcare (CHC) division. Sanofi declared that the CHC division became an independent corporation from last year. CEO Paul Hudson, who took office in September last year, mentioned CHC's strategy for an independent corporation in December of
- Policy
- α-GPC's clinical re-evaluation will proceed in 3 groups
- by Lee, Tak-Sun Nov 20, 2020 06:15am
- While Korea United Pharm has visualized a separate clinical trial to verify the effect of 'mild cognitive impairment', Daewoong and Chong Kun Dang, which are ranked first and second in market sales, are expected to conduct clinical trials for all indications. The three companies plan to hold briefing sessions for related companies next week
- Company
- "TNF blockers in rheumatoid arthritis is a symbol of trust"
- by Eo, Yun-Ho Nov 20, 2020 06:14am
- A tumor necrosis factor (TNF)-α inhibitor was a game changer for the rheumatoid arthritis (RA) treatment scene. An autoimmune disease RA, which causes break down in joints and bone tissues with abnormal immune reaction, has prevalence rate in female patients approximately 0.3 percent to 1 percent higher than male patients. According
- Company
- Protecting labor rights in multinational company spinoff
- by Nov 20, 2020 06:12am
- The multinational pharmaceutical companies in South Korea came under fire after they started restructuring and downsizing unilaterally and the experts are urging for the labors’ rights to participate and choose should to be secured. On Nov. 18, a member of the National Assembly Environment and Labor Committee and Democratic Party Lawmaker
